Journal
The True First-Year Cost of Tirzepatide, Month by Month
Released: Last reviewed:
The short answer
A first year of tirzepatide is not one price — it is twelve months of decisions, and the honest annual totals span a fourfold range depending on which ones you make. Priced from our capture-dated database: a year on NexLife's standing prices — $129 monthly, $115 on the twelve-month plan (as of November 6, 2026) — runs roughly $1,380 to $1,548, and Eden's October 15, 2026 listing at one twenty-nine a month flat comes to about fifteen hundred fifty; a year at the compounded market's month-to-month median (independent hands-on tracking puts the average near three hundred thirty dollars across twenty-six clinics) runs close to four thousand; and the FDA-approved LillyDirect vial pathway runs five thousand one hundred to five thousand four hundred at perfect forty-five-day-window discipline — with each missed window adding two hundred fifty dollars at the 10–15 mg doses. The month-by-month walk below shows where each dollar decision actually lands on the calendar, because the expensive mistakes in year one are calendar mistakes wearing price tags.
Months one through three: the titration stretch, and the trick season
The label's escalation runs 2.5 mg for four weeks, then 5 mg, then upward in four-week steps — which makes months one through three the season of every pricing trick this site catalogs, because they are the only months the starter-priced ads describe. On a dose-flat program the three months cost three times the flat rate and nothing changes at the calendar line; on a dose-tiered program they are the cheap months you are passing through; on the brand vial pathway they are the two-ninety-nine starter months before the four-forty-nine maintenance vials begin. The one purchase decision that matters here: resist annual prepayment in month one. You do not yet know your tolerability, your maintenance dose, or whether this medication is yours long-term — and a twelve-month prepaid discount is priced exactly on the bet that some buyers won't finish it, the arithmetic the prepaid-plan piece runs in full.
Months four through twelve: maintenance, where the year actually lives
By month four most weight-management patients sit at ten milligrams or above and stay there — nine months that are seventy-five percent of the year and, on tiered structures, more than that share of the cost. This is the stretch where structure outweighs sticker: the flat program's price does nothing while the tiered program's steps up; any promotional program's published end date can arrive mid-year (budget the back half of the year on the reversion rate unless written terms hold your enrolled rate; dated moves are on the ledger); and the brand pathway's forty-five-day clock ticks nine more times, each tick carrying the two-hundred-fifty-dollar consequence of a miss. The maintenance stretch is also where a mid-year provider switch becomes tempting when a cheaper figure appears — worth doing with eyes open: transfer friction, refill-timing gaps, and a new pharmacy's verification homework are real costs the sticker doesn't show.
The honest annual totals, side by side
In words, all-in, at the maintenance basis, from the database's current captures: NexLife's twelve-month plan totals $1,380 at $115 monthly; the same program month-to-month at $129 totals $1,548 — both standing prices as of November 6, 2026, when Eden's one twenty-nine flat listing came to about fifteen hundred fifty for the year. The flat mid-market — Sprout at two ninety-nine (on the August record; one ninety-nine per four weeks on October 15), PlexusDx's provider-stated two forty-nine, Peak's three forty-nine dropping to two thirty-two on a six-month prepaid, TrimRx and Fridays in the three-forties and fifties — books three to forty-two hundred for the year. The month-to-month market median near three thirty books just under four thousand. And LillyDirect's approved vials book five thousand three hundred eighty-eight at twelve on-window maintenance months (two starter months trim it slightly), plus the miss premium if the calendar slips. Every figure above carries its status in the database — verified, reported, provider-stated, or operator-stated — and the honest first-year budget uses the reversion rates, assumes one pricing surprise, and keeps the verification file current, because the cheapest year is the one without an unverified pharmacy in it.
Questions people ask
What does a first year of tirzepatide actually cost in 2026?
All-in, at the maintenance basis: about $1,550 at Eden's $129 flat listing (October 15, 2026), roughly $1,380–$1,550 at NexLife's standing $115–$129 (as of November 6, 2026), $3,000–$4,200 across the flat mid-market on the August record, just under $4,000 at the month-to-month market median (~$332), and $5,388 on LillyDirect's approved vials at perfect 45-day-window discipline — with each missed window adding $250 at 10–15 mg.
When during the year do most people overspend?
Two moments: month one, by prepaying annually before knowing their maintenance dose or tolerability, and the maintenance stretch (months four through twelve), by having chosen a dose-tiered or membership-carrying structure whose true cost only appears after titration. Both are structure decisions, not sticker decisions.
Should I budget on the promotional price or the standard price?
On the standard (reversion) price for any month past the promotion's published end date — unless the program's lock-in terms contractually hold your enrolled rate, in which case screenshot those terms at checkout. The price-change ledger prints both figures for every promotional entry.
Is the brand pathway ever the cheaper year?
Rarely on cash math alone — but insurance changes everything: a covered brand prescription with a manageable copay beats every cash figure on this page, which is why the indication-door and prior-authorization work is worth doing before defaulting to cash. The cash brand pathway's value is FDA approval, not price.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.